PTC Therapeutics, Inc. Sets New 1-Year High at $24.38 (PTCT)
PTC Therapeutics (NASDAQ:PTCT) set a new 52-week high during trading on Monday, AnalystRatings.Net reports. The stock traded as high as $24.38 and last traded at $23.38, with a volume of 374,485 shares. The stock had previously closed at $17.88.
A number of analysts have recently weighed in on PTCT shares. Analysts at Wedbush reiterated a “buy” rating on shares of PTC Therapeutics (NASDAQ:PTCT) in a research note to investors on Monday. Separately, analysts at Jefferies Group raised their price target on shares of PTC Therapeutics (NASDAQ:PTCT) from $25.00 to $28.00 in a research note to investors on Friday, July 26th. Finally, analysts at Cowen and Company initiated coverage on shares of PTC Therapeutics (NASDAQ:PTCT) in a research note to investors on Friday, July 26th. They set an “outperform” rating and a $33.00 price target on the stock.
Four analysts have rated the stock with a buy rating, PTC Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.98.
PTC Therapeutics has a 1-year low of $1.563 and a 1-year high of $22.37. The stock has a 50-day moving average of $17.35 and a 200-day moving average of $15.90. The company has a market cap of $535.1 million and a price-to-earnings ratio of 2.99.
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.